Register for email alerts and news feeds:
This journal | BMJ Group
rss
Archives of Disease in Childhood 2001;85:478-483; doi:10.1136/adc.85.6.478
Copyright © 2001 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health.
Arch Dis Child 2001;85:478-483 ( December )

Article

De novo malignancy after paediatric renal replacement therapy H M Coutinho, J W Groothoff, M Offringa, M P Gruppen, H S A Heymans

Department of Paediatric Nephrology, Department of Paediatrics, Emma Children's Hospital AMC, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, Netherlands

Correspondence to: Dr Groothoff j.w.groothoff{at}amc.uva.nl

Accepted 13 August 2001

AIMS---To determine frequency, type, determinants, and outcome of malignancies in children with end stage renal failure.
METHODS---All Dutch patients, aged less than 15 years, who started chronic renal replacement therapy between 1972 and 1992 and who were at least 18 years old on 1 January 1997, were retrospectively studied.
RESULTS---Mean follow up from first renal replacement therapy was 15.5 years. Twenty two malignancies were found in 21 of 249 patients. Skin cancer accounted for 59% and non-Hodgkin lymphoma for 23% of malignancies. At 25 years after first renal replacement therapy, the probability of developing a malignancy was 17% (95% CI: 9 to 24%). Compared to the general population the incidence rate for overall cancer was tenfold higher. For non-melanoma skin cancer and non-Hodgkin lymphoma, standardised risks were 222 and 46 respectively. The use of more than 20 mg/kg cyclophosphamide showed an association with increased risk of malignancy. Six patients died as a result of their malignancy, accounting for 9.5% of overall mortality. Whereas four out of five patients with non-Hodgkin lymphoma died, the most frequent malignancy, skin cancer, did not contribute to mortality.
CONCLUSION---The long term risk of certain malignancies is significantly increased in children who have undergone renal replacement therapy. As an important contributor to overall mortality, awareness of this risk of malignancy in these patients is necessary, especially after treatment with cyclophosphamide.


Keywords: renal replacement therapy; malignancy; follow up


© 2001 by Archives of Disease in Childhood

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Koukourgianni, F., Harambat, J., Ranchin, B., Euvrard, S., Bouvier, R., Liutkus, A., Cochat, P. (2009). Malignancy incidence after renal transplantation in children: a 20-year single centre experience. Nephrol Dial Transplant 0: gfp497v1-gfp497 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Latest from ADC

 

ADC is co-owned by the RCPCH and is the official journal of the European Academy of Paediatrics

BMJ Careers - Latest Paediatrics and Paediatric Surgery Jobs

Paediatrics and Paediatric Surgery Jobs